Article
Clinical implications for substandard, nonproprietary medicines in multiple sclerosis…
Drug Design, Development and Therapy · 2016 · Correale J, Chiquete E, Boyko A, Beran RG, Strauch JB, Milojevic S, Frider N
Key facts
| Title | Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod |
|---|---|
| First author | Correale J, Chiquete E, Boyko A, Beran RG, Strauch JB, Milojevic S, Frider N |
| Journal | Drug Design, Development and Therapy |
| Published | Jun 30, 2016 |
| DOI | 10.2147/DDDT.S106802 |
| Devices mentioned | K964068 |
| Product codes mentioned | KLT |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1